Detection of CD30 expression in lymphomas: status and challenges

doi:10.19401/j.cnki.1007-3639.2022.06.005

Abstract

Abstract:

CD30, a member of tumor necrosis factor receptor family, is expressed in a variety of lymphoma subtypes, such as classic Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL). In addition to its diagnostic and prognostic values, CD30 has now been recognized as an effective target for antibody drug conjugate (ADC). With the progress of multiple clinical trials involving the anti-CD30-targeted therapy, a standardized detection and assessment of CD30 expression in lymphoma cases appear necessary. We thus reviewed in this article the CD30 expression patterns and the challenges on the CD30 detection and assessment in different lymphomas.

Key words: Lymphoma, CD30, Biomarker, Targeted therapy

CLC Number:

R733.4

LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges[J]. China Oncology, 2022, 32(6): 512-518.

Figures/Tables 2

Tab. 1

Tab. 2

References 36

[1]	HORIE R,, AIZAWA S,, NAGAI M, et al. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation[J]. Int Immunol, 1998, 10(2): 203-210. doi: 10.1093/intimm/10.2.203
[2]	VAN DER WEYDEN C A, PILERI S A,, FELDMAN A L, et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions[J]. Blood Cancer J, 2017, 7(9): e603. doi: 10.1038/bcj.2017.85
[3]	ROMAGNANI P,, ANNUNZIATO F,, MANETTI R, et al. High CD30 ligand expression by epithelial cells and Hassal's corpuscles in the medulla of human thymus[J]. Blood, 1998, 91(9): 3323-3332. doi: 10.1182/blood.V91.9.3323
[4]	BOWEN M A,, LEE R K,, MIRAGLIOTTA G, et al. Structure and expression of murine CD30 and its role in cytokine production[J]. J Immunol, 1996, 156(2): 442-449.
[5]	PIERCE J M,, MEHTA A. Diagnostic, prognostic and therapeutic role of CD30 in lymphoma[J]. Expert Rev Hematol, 2017, 10(1): 29-37. doi: 10.1080/17474086.2017.1270202
[6]	FEDERICO M,, BELLEI M,, LUMINARI S, et al. CD30⁺ expression in peripheral T-cell lymphomas (PTCLs): a subset analysis from the international, prospective T-Cell Project[J]. J Clin Oncol, 2015, 33(15_suppl): 8552. doi: 10.1200/jco.2015.33.15_suppl.8552
[7]	PONGPRUTTIPAN T,, KUMMALUE T,, BEDAVANIJA A, et al. Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand[J]. Diagn Pathol, 2011, 6: 79. doi: 10.1186/1746-1596-6-79
[8]	FERRERI A J M,, GOVI S,, PILERI S A, et al. Anaplastic large cell lymphoma, ALK-positive[J]. Crit Rev Oncol, 2012, 83(2): 293-302. doi: 10.1016/j.critrevonc.2012.02.005
[9]	DELSOL G,, FALINI B,, MULLERHERMELINK HK, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. WHO classification of tumours of haematopoietic & lymphoid tissues, 2008[EB/OL].[2008-01-01].https://www.researchgate.net/scientific-contributions/HK-Muller-Hermelink-2127932347 .
[10]	SABATTINI E,, PIZZI M,, TABANELLI V, et al. CD30 expression in peripheral T-cell lymphomas[J]. Haematologica, 2013, 98(8): e81-e82.
[11]	EDINGER J T,, CLARK B Z,, PUCEVICH B E, et al. CD30 expression and proliferative fraction in nontransformed mycosis fungoides[J]. Am J Surg Pathol, 2009, 33(12): 1860-1868. doi: 10.1097/PAS.0b013e3181bf677d
[12]	CERRONI L,, RIEGER E,, HÖDL S, et al. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma[J]. Am J Surg Pathol, 1992, 16(6): 543-552. doi: 10.1097/00000478-199206000-00002
[13]	EL SHABRAWI-CAELEN L, KERL H,, CERRONI L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C[J]. Arch Dermatol, 2004, 140(4): 441-447.
[14]	SLACK G W,, STEIDL C,, SEHN L H, et al. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia[J]. Br J Haematol, 2014, 167(5): 608-617. doi: 10.1111/bjh.13085
[15]	CAMPUZANO-ZULUAGA G,, CIOFFI-LAVINA M,, LOSSOS I S, et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases[J]. Leuk Lymphoma, 2013, 54(11): 2405-2411. doi: 10.3109/10428194.2013.778407
[16]	HU S M,, XU-MONETTE Z Y,, BALASUBRAMANYAM A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL rituximab-CHOP consortium program study[J]. Blood, 2013, 121(14): 2715-2724. doi: 10.1182/blood-2012-10-461848
[17]	HIGGINS J P,, WARNKE R A. CD30 expression is common in mediastinal large B-cell lymphoma[J]. American J Clin Pathol, 1999, 112(2): 241-247. doi: 10.1093/ajcp/112.2.241
[18]	GARDNER L J,, POLSKI J M,, EVANS H L, et al. CD30 expression in follicular lymphoma[J]. Archiv Pathol Laboratory Med, 2001, 125(8): 1036-1041. doi: 10.5858/2001-125-1036-CEIFL
[19]	ANSELL S M. Hodgkin lymphoma: diagnosis and treatment[J]. Mayo Clin Proc, 2015, 90(11): 1574-1583. doi: 10.1016/j.mayocp.2015.07.005
[20]	MORA J,, FILIPPA D A,, THALER H T, et al. Large cell non-Hodgkin lymphoma of childhood[J]. Cancer, 2000, 88(1): 186-197. doi: 10.1002/(SICI)1097-0142(20000101)88:1<186::AID-CNCR26>3.0.CO;2-5
[21]	KRAUSE J R. WHO classification of tumours of haematopoietic and lymphoid tissues: an overview[J]. Crit Values, 2015, 2(2): 30-32.
[22]	WEISENBURGER D D,, SAVAGE K J,, HARRIS N L, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project[J]. Blood, 2011, 117(12): 3402-3408. doi: 10.1182/blood-2010-09-310342
[23]	HOFFBRAND A,, CATOVSKY D,, TUDDENHAM E, et al. Appendix Ⅱ: World Health Organization classification of tumours of the haematopoietic and lymphoid tissues[EB/OL]. https://www.who.int/publications/i?publishingoffices=c09761c0-ab8e-4cfa-9744-99509c4d306b , 2010.
[24]	FALINI B,, PILERI S,, PIZZOLO G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy[J]. Blood, 1995, 85(1): 1-14. doi: 10.1182/blood.V85.1.1.bloodjournal8511
[25]	EL-SAYED A M,, EL-BORAI M H,, BAHNASSY A A, et al. Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry[J]. Diagn Pathol, 2008, 3: 43. doi: 10.1186/1746-1596-3-43 pmid: 18986555
[26]	Nordic Immunohistochemical Quality Control, CD30 run 51 2017.[EB/OL].[2017-11-27]. https://www.nordiqc.org/downloads/assessments/90_5.pdf
[27]	LI B,, ESCHRICH S A,, BERGLUND A, et al. Use of the total cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility[J]. JMIR Res Protoc, 2017, 6(3): e45.
[28]	XU M L,, GABALI A,, HSI E D, et al. Practical approaches on CD30 detection and reporting in lymphoma diagnosis[J]. Am J Surg Pathol, 2020, 44(2): e1-e14.
[29]	HORWITZ S,, O'CONNOR O A,, PRO B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial[J]. Lancet, 2019, 393(10168): 229-240. doi: 10.1016/S0140-6736(18)32984-2
[30]	FANALE M A,, HORWITZ S M,, FORERO-TORRES A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30⁺ peripheral T-cell lymphomas: results of a phase I study[J]. J Clin Oncol, 2014, 32(28): 3137-3143. doi: 10.1200/JCO.2013.54.2456
[31]	DUVIC M,, TETZLAFF M T,, GANGAR P, et al. Results of a phase Ⅱ trial of brentuximab vedotin for CD30⁺ cutaneous T-cell lymphoma and lymphomatoid papulosis[J]. J Clin Oncol, 2015, 33(32): 3759-3765. doi: 10.1200/JCO.2014.60.3787
[32]	PRINCE H M,, KIM Y H,, HORWITZ S M, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390(10094): 555-566. doi: 10.1016/S0140-6736(17)31266-7
[33]	HORWITZ S M,, ADVANI R H,, BARTLETT N L, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin[J]. Blood, 2014, 123(20): 3095-3100. doi: 10.1182/blood-2013-12-542142
[34]	ZINZANI P L,, SANTORO A,, GRITTI G, et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase Ⅱ CheckMate 436 study[J]. J Clin Oncol, 2019, 37(33): 3081-3089. doi: 10.1200/JCO.19.01492
[35]	KIM Y H,, TAVALLAEE M,, SUNDRAM U, et al. Phase Ⅱ investigator-initiated study of brentuximab vedotin in mycosis fungoides and sézary syndrome with variable CD30 expression level: a multi-institution collaborative project[J]. J Clin Oncol, 2015, 33(32): 3750-3758. doi: 10.1200/JCO.2014.60.3969
[36]	JACOBSEN E D,, SHARMAN J P,, OKI Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression[J]. Blood, 2015, 125(9): 1394-1402. doi: 10.1182/blood-2014-09-598763

Reference	Subtype	CD30 positive/%
Federico^[6]	Peripheral T-cell lymphoma-unspecified (PTCL-NOS)	59
	Angioimmunoblastic T-cell lymphoma (AITL)^*	76
Federico and Pongpruttipan^[6-7]	Extranodal NK/T cell lymphoma, nasal type (ENKTCL)	52-75
Ferreri and Delsol^[8-9]	ALCL, anaplastic lymphoma kinase (ALK)⁺/ALK^-	100
Sabattini^[10]	Enteropathy associated T-cell lymphoma (EATL)	54-100
Edinger^[11]	MF/Sézary syndrome	11-100
Cerroni^[12]	Transformative MF	100
El Shabrawi-Caelen^[13]	Lymphomatoid papulosis (LyP)	60-100
Slack, Campuzano-Zuluaga and Hu^[14⇓-16]	DLBCL	14-25
Slack^[14]	DLBCL, EB virus positive	90
Higgins^[17]	Primary mediastinal large B-cell lymphoma (PMBL)	69
Gardner^[18]	Follicular lymphoma (FL)	36-50

Reference	Study type	Pathological type	Case n	CD30 positive/%	ORR/PFS
Fanale^[30]	Ⅰ	PTCL	26	1	100.0%
Weisenburger^[22]		PTCL-NOS	340	20	Not reported
Duvic^[31]	Ⅱ	Cutaneous T-cell lymphoma	48	10	73.0%
Prince^[32]	Ⅲ	Cutaneous T-cell lymphoma	131	10	56.3%
Horwitz^[29]	Ⅲ	PTCL	452	10	PFS 48.2 month (vs 20.8 month)
Horwitz^[33]	Ⅱ	PTCL-NOS and PTCL-AITL	35	15%	41.0%
Zinzani^[34]	Ⅰ/Ⅱ	PMBL	30	1%	73.0%
Kim^[35]	Ⅱ	MF/Sézary syndrome	30	5%	70.0%
Campuzano-Zuluaga^[15]		DLBCL	167	20%	Not reported
Jacobsen^[36]	Ⅱ	Recurrent/refractory DLBCL	49	1%	44.0%